10 Percent of U.S. Installed Base Signs on to Use Accuray Treatment Planning Service
(Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today
that 10 percent of its U.S. installed base has signed on to utilize the
company’s treatment planning service. Treatment planning by medical physicists
is a core component in the workflow of CyberKnife radiosurgery treatment
delivery.
Accuray’s treatment planning service is designed to help customers
maximize utilization of their CyberKnife System. The service connects each
center’s physics team to a group of remote medical physics experts who
specialize in CyberKnife radiosurgery treatment planning. It can serve as a
supplement for centers that require additional support to meet growing patient
volumes without increasing their fixed costs. Each center can immediately take
advantage of added capacity to treat more patients without altering their own
staffing.
“Accuray’s Treatment Planning Service has worked extremely well for us.
Their service and expert group of experienced medical physicists have helped
us to provide the highest level of care to our patients,” said
director, Radiation Oncology, Carolinas Medical Center-North East.
It also can serve as a contingency plan to help protect sites from
unplanned fluctuations in staffing that they may face in a given year. By
providing a pathway for collaboration with expert physicists, new customers
can gain confidence, share knowledge, and begin delivering more complex
CyberKnife treatments faster.
“In these challenging economic times, we recognize the importance of
offering our customers resources that help them control costs and increase
their patient throughput,” said
Accuray Incorporated. “We are pleased to see that a number of our customers
are taking advantage of our treatment planning service as a tool to grow and
run their business more efficiently.”
Of the U.S. Centers that have signed on to utilize Accuray’s treatment
planning service, 30 percent have signed agreements for a fixed volume of use
and the remainder are set up for service on demand.
The treatment planning service also offers specialized remote access
capabilities, which enable physicians located outside of the CyberKnife
facility a convenient mechanism to refer and plan their patients without
having to drive to the facility. This convenience allows clinicians to
seamlessly collaborate with the on-site staff thereby reducing the planning
cycle time and enhancing the operational effectiveness of the planning
process.
About the CyberKnife(R) Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world’s only robotic
radiosurgery system designed to treat tumors anywhere in the body non-
invasively. Using continual image guidance technology and computer controlled
robotic mobility, the CyberKnife System automatically tracks, detects and
corrects for tumor and patient movement in real-time throughout the treatment.
This enables the CyberKnife System to deliver high-dose radiation with
pinpoint precision, which minimizes damage to surrounding healthy tissue and
eliminates the need for invasive head or body stabilization frames.
About Accuray
Accuray Incorporated (Nasdaq: ARAY), based in
global leader in the field of radiosurgery dedicated to providing an improved
quality of life and a non-surgical treatment option for those diagnosed with
cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery
System, which extends the benefits of radiosurgery to include extracranial
tumors, including those in the spine, lung, prostate, liver and pancreas. To
date, the CyberKnife System has been used to treat more than 50,000 patients
worldwide and currently more than 155 systems have been installed in leading
hospitals in the Americas,
http://www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve
risks and uncertainties, including uncertainties associated with the medical
device industry. Except for the historical information contained herein, the
matters set forth in this press release, including statements relating to
clinical studies, regulatory review and approval, and commercialization of
products are forward-looking statements within the meaning of the “safe
harbor” provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements speak only as of the date the statements are made
and are based on information available at the time those statements are made
and/or management’s good faith belief as of that time with respect to future
events. You should not put undue reliance on any forward-looking statements.
Important factors that could cause actual performance and results to differ
materially from the forward-looking statements we make include: market
acceptance of products; competing products, the combination of our products
with complementary technology; and other risks detailed from time to time
under the heading “Risk Factors” in our report on Form 10-K for the 2008
fiscal year, as updated in our Form 10-Q filed on
other filings with the Securities and Exchange Commission. The Company’s
actual results of operations may differ significantly from those contemplated
by such forward-looking statements as a result of these and other factors. We
assume no obligation to update forward-looking statements to reflect actual
performance or results, changes in assumptions or changes in other factors
affecting forward-looking information, except to the extent required by
applicable securities laws.
SOURCE Accuray Incorporated